flâneur

Gregory Verdine Finds Ways To ‘Drug the Undruggable’ Diseases | Harvard Medical School

hms.harvard.edu · 111 words · saved by 1 readers

Force behind pancreatic cancer progress learned improvisational thinking from a devastating family accident Chemical biologist Gregory Verdine was driving from his home north of Boston to his office in Cambridge when he had to pull over. Verdine — the Erving Professor of Chemistry in the Department of Stem Cell and Regenerative Biology and of Chemistry and Chemical Biology, Emeritus, at Harvard University and Harvard Medical School — was listening to the podcast Interesting Times with Ross Douthat. The guest was former U.S. Sen. Ben Sasse, who has stage 4 (metastatic) pancreatic cancer. Few with the diagnosis survive beyond a year. Get more HMS news Sasse sounded surprisingly upbeat as he described an experimental drug that had reduced his tumors by 76 percent and helped him beat survival expectations (though not cure him, he noted). “I did that,” Verdine recalled thinking. “I made that possible.” The drug was daraxonrasib, which garnered attention in May for its unprecedented success

Pardon Our Interruption As you were browsing something about your browser made us think you were a bot. There are a few reasons this might happen: You're a power user moving through this website with super-human speed. You've disabled cookies in your web browser. A third-party browser plugin, such as Ghostery or NoScript, is preventing JavaScript from running. Additional information is available in this support article . To regain access, please make sure that cookies and JavaScript are enabled before reloading the page. Please stand by We're getting everything ready for you. The page is loadi

related reading